Last reviewed · How we verify
NCT02720445: MIND
Memory Improvement Through Nicotine Dosing (MIND) Study
Phase 2 trial testing Nicotine Transdermal Patch in Mild Cognitive Impairment in 348 participants. Completed in 16 September 2025.
25 August 2025
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 348 |
| Start date | 13 January 2017 |
| Primary completion | 25 August 2025 |
| Estimated completion | 16 September 2025 |
| Sites | 36 locations across United States |
Drugs / interventions tested
- Nicotine Transdermal Patch — full drug profile →
- Placebo Patch
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
University of Southern California
Who can join
Adults 55 to 90, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008 -
Alzheimer's disease drug development pipeline: 2018.
Cummings J, Lee G, Ritter A, Zhong K. · · 2018 · cited 402× · PMID 29955663 · DOI 10.1016/j.trci.2018.03.009 -
Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295 -
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050 -
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2023 · cited 326× · PMID 37251912 · DOI 10.1002/trc2.12385 -
Alzheimer's disease drug development pipeline: 2021.
Cummings J, Lee G, Zhong K, Fonseca J, et al · · 2021 · cited 312× · PMID 34095440 · DOI 10.1002/trc2.12179 -
Pathological mechanisms and therapeutic strategies for Alzheimer's disease.
Ju Y, Tam KY. · · 2022 · cited 260× · PMID 34380884 · DOI 10.4103/1673-5374.320970 -
Alzheimer's disease drug development pipeline: 2017.
Cummings J, Lee G, Mortsdorf T, Ritter A, et al · · 2017 · cited 258× · PMID 29067343 · DOI 10.1016/j.trci.2017.05.002
Verify or expand the search:
- PubMed search for NCT02720445
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nicotine Transdermal Patch
Trials testing the same drug.
- NCT04468230 — Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy · Phase 2 · terminated
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02720445 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02720445.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing